secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2025-08-19T23:59:59+00:00
Accession:  0001213900-25-078162
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx appoints Brendan Merrell COO; expands Stelmakh, Odence-Ford, D'Silva roles
--------------------------------------------------------------------------------

- Brendan Merrell named COO effective Aug 18, 2025; base salary $325k, target bonus 40%.
- Ed Stelmakh becomes Chief Financial & Strategic Officer, adding corporate strategy to finance duties.
- Marion Odence-Ford promoted to Chief Legal & Administrative Officer, adding admin oversight.
- Andy D'Silva promoted to Chief Business Officer, leading FP&A, IR, and strategic planning.
- Changes designed to accelerate Rule of 40 strategy (sustained growth + profitability) over 2-3 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000121390025078162/0001213900-25-078162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000121390025078162/ea0253741-8k_optimize.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-078162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer